-- Deemed dividend
Use of Non-GAAP Financial Measures
Amicus' "non-GAAP net loss" and "non-GAAP diluted net loss per common
share" financial measures are defined as reported, or GAAP net loss and
diluted net loss per common share excluding certain items further discussed
below. Amicus' management uses these non-GAAP financial measures to
establish financial goals and to gain an understanding of the comparative
financial performance of Amicus from year to year and quarter to quarter.
Accordingly, Amicus believes investors' understanding of Amicus' financial
performance is enhanced as a result of disclosing these non-GAAP financial
measures. Non-GAAP net loss and diluted net loss per common share should
not be viewed in isolation or as a substitute for reported, or GAAP net
loss and diluted net loss per common share.
(1) Stock option expense - Non-GAAP net loss and diluted net loss per
common share exclude the impact of the stock option expense recorded
in accordance with SFAS No. 123R. Amicus believes that excluding the
impact of expensing stock options better reflects the recurring
economic characteristics of its business.
(2) Other items - Non-GAAP net loss and diluted net loss per common share
exclude other unusual or non-recurring items that are evaluated on an
individual basis. Amicus' evaluation of whether to exclude an item for
purposes of determining its non-GAAP financial measures considers both
the quantitative and qualitative aspects of the item, including, among
other things (i) its size and nature, (ii) whether or not it relates
to its ongoing business operations, and (iii) whether or not Amicus
expects it to occur as part of its normal business on a regular basis.
Items excluded for purposes of determining non-GAAP net loss and
diluted net loss per common sh
|SOURCE Amicus Therapeutics|
Copyright©2008 PR Newswire.
All rights reserved